Leishmaniasis is one of the most neglected tropical disease in terms of
drug discovery and development. Most antileishmanial drugs are highly
toxic, present resistance issues or require hospitalization, being
therefore not adequate to the field. Recently improvements have been
achieved by combination therapy, reducing the time and cost of
treatment. Nonetheless, new drugs are still urgently needed.
In this review, we describe the current visceral leishmaniasis (VL)
treatments and their limitations. We also discuss the new strategies in
the drug discovery field including the development and implementation of
high-throughput screening (HTS) assays and the joint efforts of
international teams to deliver clinical candidates.
Freitas-Junior, L.H.; Chatelain, E.; Andrade Kim, H.; Siqueira-Neto, J.L. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? International Journal for Parasitology: Drugs and Drug Resistance (2012) 2: 11-19. [DOI: 10.1016/j.ijpddr.2012.01.003]
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?